Speaker illustration

Professor Hiddo Heerspink

University Medical Center Groningen, Groningen (Netherlands (The))

Q&A - Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.

Event: ESC Asia with APSC & AFC 2020

Topic: Renal Failure and Cardiovascular Disease

Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i

Thumbnail

Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.

Event: ESC Asia with APSC & AFC 2020

Topic: Renal Failure and Cardiovascular Disease

Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i

Thumbnail

What are the mechanisms linking novel antidiabetic treatments to cardiovascular benefit?

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Diabetes and the Heart

Session: Balancing Treatment Needs for Diabetic Patients with Cardiovascular Disease

Thumbnail

Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Antidiabetic Pharmacotherapy

Session: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

Thumbnail

DAPA-CKD - Dapagliflozin in Patients with Chronic Kidney Disease

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Renal Failure and Cardiovascular Disease

Session: Hot Line DAPA-CKD

Thumbnail

Hot Line DAPA-CKD.

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Renal Failure and Cardiovascular Disease

Session: Hot Line DAPA-CKD

Thumbnail

This platform is supported by

logo Novo Nordisk